ANI Pharmaceuticals Inc  

(Public, NASDAQ:ANIP)   Watch this stock  
Find more results for NASDAQ:BPAX
30.52
-0.66 (-2.12%)
Jul 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 30.40 - 31.31
52 week 5.99 - 38.74
Open 30.95
Vol / Avg. 107,903.00/184,545.00
Mkt cap 344.69M
P/E 14.73
Div/yield     -
EPS 2.07
Shares 11.28M
Beta 2.00
Inst. own 71%
May 5, 2014
Q1 2014 ANI Pharmaceuticals, Inc. Earnings Conference Call
May 5, 2014
Q1 2014 ANI Pharmaceuticals, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 30.82% 0.35%
Operating margin 32.07% 2.99%
EBITD margin - 6.68%
Return on average assets 19.09% 0.36%
Return on average equity 20.05% -
Employees 81 -
CDP Score - -

Address

210 MAIN STREET WEST
BAUDETTE, MN 56623
United States - Map
+1-218-6343500 (Phone)
+1-218-6343540 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing and marketing branded and generic prescription pharmaceuticals. It manufactures oral solid dose products, as well as liquids and topicals, including narcotics. Its other products include The Food and Drug Administration approved testosterone gel, which is licensed to Teva Pharmaceuticals USA. It performs contract manufacturing for other pharmaceutical companies. The Company has launched three products and has 11 products in development. Its targeted areas of product development include narcotics, anti-cancers and hormones (potent compounds), and extended release niche generic product opportunities. In December 2013, the Company acquired 31 generic drug products from Teva Pharmaceuticals, which includes 20 solid-oral immediate release products, four extended release products and seven liquid products.

Officers and directors

Robert E. Brown Jr. Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Arthur S. Przybyl President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Charlotte C. Arnold Chief Financial Officer, Vice President
Age: 51
Bio & Compensation  - Reuters
James G. Marken Vice President - Operations
Age: 51
Bio & Compensation  - Reuters
Robert J. Jamnick Vice President - Quality and Product Development
Age: 56
Bio & Compensation  - Reuters
Robert W. Schrepfer Vice President - New Business Development and Contract Manufacturing
Age: 42
Bio & Compensation  - Reuters
Thomas A. Penn Director
Age: 68
Bio & Compensation  - Reuters
Fred H. Holubow Independent Director
Age: 75
Bio & Compensation  - Reuters
Ross J. Mangano Independent Director
Age: 68
Bio & Compensation  - Reuters
Tracy L. Marshbanks Ph.D. Independent Director
Age: 50
Bio & Compensation  - Reuters